RESEARCH ARTICLE

Risk of cardiovascular disease in Chinese patients with rheumatoid arthritis: A cross-sectional study based on hospital medical records in 10 years

Kun Zou1,2,*, Fu-Kun Xiao1, Hong-Ying Li1, Qiao Zhou3, Lu Ban2,4, Min Yang5, Chang-Fu Kuo2,6, Weiya Zhang2

1 Department of Medical Records and Statistics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Affiliated Hospital of the University of Electronic Science and Technology, Chengdu, China, 2 Division of Rheumatology, Orthopedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 3 Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Affiliated Hospital of the University of Electronic Science and Technology, Chengdu, China, 4 Division of Epidemiology & Public Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 5 West China Research Center for Rural Health Development, West China School of Public Health, Sichuan University, Chengdu, China, 6 Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

* zoukun.jy@outlook.com

Abstract

Objective

Though the risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been established in Western population, little is known about the risk in Chinese people with RA. Our objective was to estimate the risk of CVD in Chinese people with RA using hospital medical records data.

Methods

The inpatients medical record database 2005–2015 of Sichuan provincial people’s hospital was examined. All individuals with a primary diagnosis of RA were included as cases, and those of osteoarthritis (OA) were included as controls, which consisted of the unmatched dataset. Then, RA cases and OA controls were matched by sex and age at 1:1 ratio, forming the matched dataset. The morbidity of CVD (including ischemia heart disease (IHD), congestive heart failure (CHF), et al), stroke and artherosclerosis were extracted from the database, so as the demographic data and comorbidities related to CVD. Multiple logistic regression analysis was used to estimate the risk of CVD in RA adjusted for demographics and comorbidities using the unmatched dataset. Sensitivity analysis was conducted 1) considering interaction terms between RA and comorbidities, and 2) using multivariable conditional logistic regression for the matched dataset.

Results

The unmatched dataset comprised of 1824RA cases and 1995 OA controls and the matched dataset comprised of 1022 pairs of sex and age matched RA and OA patients. RA
exhibited increased odds of prevalent CVD compared with OA, and the adjusted ORs (95% CIs) for CVD, stroke, IHD, CHF, and atherosclerosis were 1.86 (1.42–2.43), 1.11 (0.71–1.74), 1.47 (0.97–2.24), 2.09 (1.03–4.22), and 2.49 (1.97–3.13), respectively, and was 2.26 (1.29–3.96) for IHD further adjusted for interaction term. The matched dataset analysis found similar results.

Conclusions
Chinese people with RA were approximated 2 times more likely to have CVD, IHD, CHF and atherosclerosis compared with those with OA. The findings justified the need of further longitudinal study to establish the causal-relationship between RA and CVD and to estimate the precise risk in this population.

Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease associated with persistent inflammatory synovitis, progressive joint destruction, and an excess mortality when compared to the non-RA individuals.[1–5] RA affects estimated 0.42% of the Chinese population, approximately 5,745,600 people.[6] It is evident that RA increases the risk of cardiovascular diseases (CVD) in addition to traditional CVD risk factors.[2] Systemic inflammation and the ‘accelerated atherosclerosis’ in RA are considered as the main mechanism linking RA and CVD.[7] Osteoarthritis (OA)—a leading cause of pain and disability, is generally considered as a chronic wear and tear joint condition without systemic inflammation, thus was employed as non-systemic inflammatory comparator in previous studies.[8, 9][4] However, the risk of CVD in Chinese people with RA is unclear and evidence from epidemiological study is lacking. Acknowledge of the relative risk is relevant for optimal management and care of people with RA and prevention of CVD.[10] The objective of this study was to estimate the risk of CVD in Chinese people with RA comparing with those with osteoarthritis (OA) as controls.

Methods
Data source and patient definition
The study was approved by the Ethics Committee of Sichuan Provincial People’s Hospital (SPPH) on using anonymous medical records data for scientific research purpose (No. 2016–27). This cross-sectional study used the inpatients medical record database (MRD) of SPPH, which records demographics, diagnoses (using ICD-10 codes), procedures (using ICD-CM-9 codes) and expenditure of all inpatients from 2005–2015. All patients with a principal discharge diagnosis of RA (ICD-10 codes: M05.0-M06.9) from 2005–2015 were included, and all patients with a principal discharge diagnosis of OA (ICD-10 codes: M15.0-M19.9) were selected as controls. We focused on the principal diagnosis of discharge to maximize the validity of the case and control definition. Patients with discharge diagnosis of both RA and OA were excluded to avoid the overlapping effect.

Two datasets were generated. The first is an unmatched dataset containing all included RA or OA patients. The second was the matched dataset in which patients with RA and OA were matched at 1:1 ratio by sex and age (per 5 years), which was used for the sensitivity analysis.
Cardiovascular diseases

The primary outcomes in this study were CVD and stroke. Secondary outcomes were specific cardiovascular conditions: ischaemic heart diseases (IHD), congestive heart failure (CHF) and atherosclerosis (AS). All outcomes were defined by diagnoses recorded in the MRD using ICD-10 codes (S1 Table).[11]

Covariates or confounders

Confounders considered were age, gender, and comorbidities related to CVD including hypertension, hyperlipidemia, diabetes mellitus or hyperglycaemia (referred as the diabetes mellitus in the rest of the text) and chronic obstructive pulmonary disease (COPD).[9, 12–15] Gender and age were extracted from the MRD. Comorbidities were defined by secondary diagnoses of discharge which were recorded in the database using ICD-10 codes (S1 Table).[11]

Statistical analysis

Characteristics of participants were described before the association analyses. Continuous and categorical variables were described using mean and standard deviation (SD) and frequency and percentage, respectively. For univariate analysis, ANOVA was conducted for the former, and Chi square test for the latter.

Logistic regression was used to estimate the associations between RA and CVD outcomes using the unmatched dataset, in which unadjusted and adjusted odds ratios (ORs) with its 95% confidence intervals (CIs) were estimated, considering all covariates describe above. Sensitivity analysis was conducted 1) considering significant interaction terms of RA and comorbidities using the unmatched dataset, and 2) using multivariable conditional logistic regression analysis for the matched dataset. Model fit was tested using Bayesian information criterion (BIC). [16] All statistical analyses were conducted using STATA 13.0. The significance level was 0.05.

Results

Participants and characteristics

There were 2,235 OA patients and 3914 RA patients identified from the database between 2005 and 2015. After removing patients with discharge diagnoses of both OA and RA, 2184 patients with OA and 2390 with RA remained. Then, readmissions were removed and the last record of a patient hospitalization was selected, leaving 1995 patients with OA and 1824 patients with RA, which consisted of the unmatched dataset of 3819 participants. Finally, RA and OA patients were matched by sex and age (per 5 years), forming the matched dataset of 2044 patients with either OA or RA (1022 each) (Fig 1).

The characteristics of participants with RA (cases) and OA (controls) are presented and compared in Table 1. In the unmatched dataset, patients with OA were significantly older (63.0 vs. 52.4 years), with more women (74.6% vs. 69.6%), hypertension (22.1% vs. 10.6%), hyperlipidemia (11.6% vs. 5.0%) and less COPD (2.0% vs. 4.3%) compared with patients with RA. There was no significant difference of diabetes mellitus between the two groups. In the matched dataset, age, sex, and the proportion of patients with hypertension, hyperlipidemia, IHD or stroke was similar between the two groups. However, there were significantly more diabetes mellitus (p = 0.01) and COPD (p = 0.00) in RA cases than OA controls.

Association analysis

For the unmatched dataset, significant more patients with RA had CVD (adjusted OR: 1.86, 95%CI 1.42–2.43), CHF (adjusted OR: 2.09, 1.03–4.22) and atherosclerosis (adjusted OR: 2.49,
1.97–3.13) than OA patients adjusted for age, sex, hypertension, hyperlipidemia, diabetes mellitus and COPD. However, no difference was found for stroke (adjusted OR: 1.11, 0.71–1.74) and IHD (adjusted OR: 1.47, 0.97–2.24) between the two groups adjusted for other variables. (Table 2)

In the sensitivity analysis using matched dataset, the findings were similar to that of unmatched dataset analysis. Significant more patients with RA had CVD (adjusted OR: 2.19, 1.49–3.21), CHF (adjusted OR: 6.95, 1.50–32.21) and atherosclerosis (adjusted OR: 4.95, 3.36–7.28) than OA controls. Still, no difference of patients with stroke (adjusted OR: 1.13, 0.57–2.25) and IHD (adjusted OR: 1.83, 0.94–3.56) was found between the two groups adjusted for other variables. (Table 2)

Moreover, findings were similar for CVD, stroke, CHF and atherosclerosis in the sensitivity analysis considering interaction terms of RA and comorbidities using the unmatched dataset. However, patients with RA were significantly more likely to have IHD (adjusted OR: 2.26, 1.29–3.96) than patients with OA adjusted for other variables and the interaction term of RA and hypertension. (S2 Table)

Discussion

This study included 3819 Chinese patients with RA or OA consecutively admitted to a medical centre between 2005 and 2015. Important covariables such as age, sex, and comorbidities related to CVD were adjusted in the estimate of association between RA and CVD. RA and OA, CVD, and comorbidities related to CVD were defined by physician’s diagnoses recorded as ICD-10 codes in MRD, which reduced information bias and enhanced the accuracy of variable definition. We found 1) the prevalence of CVD in Chinese patients with RA admitted to hospital was 7.6%-10.3%; 2) RA patients were approximately twice more likely to have CVD, IHD, CHF and atherosclerosis than people with OA; and 3) the risk of stroke were not significantly different between the two groups, while an incremental (from non-significant to significant) risk of IHD was found when more covariables or their interaction were adjusted.
The approximately 2-fold risk of total CVD, IHD and CHF in Chinese people with RA found in this study is comparable to previous studies in other populations (mainly Caucasians). [2, 17, 18] For Chinese population, Chung and colleagues found a 38% increase of risk of acute myocardial infarction in patients with RA comparing with non-RA population in a cohort study in Taiwan; unfortunately the risk of total CVD and other specific CVD were not estimated. [19] The association between RA and CVD is further supported by our finding that the risk of atherosclerosis increased in RA, for it is considered as the main mechanism underlying RA and CVD morbidity linked by systemic inflammation. [7, 20] However, we found a positive but non-significant risk of stroke, and an incremental risk (from non-significant to significant) of IHD in people with RA when more covariates or interaction were adjusted. The increased risk of stroke and IHD in RA has been shown in large sample sized longitudinal studies and meta-analysis in other population. [2, 18] The non-significant finding of stroke and IHD may be due to the small number of events and lack of power in this study. Furthermore, the risk of CVD in RA compared with OA may not be able to be directly interpreted as the risk compared with non-RA general population. Because evidence has emerged recently that OA may also increase the risk of CVD compared with the general population, though it is still

| Table 1. Characteristics of rheumatoid arthritis (RA) cases and osteoarthritis controls (OA). |
|-----------------------------------------------|-------------------|------------------|-----------------|------------------|
|                                                | Unmatched dataset | Matched dataset  |
|                                                | OA (%) RA (%) p   | OA (%) RA (%) p  |
| No. of participants                            | 1,995 1,824       | 1,022            |
| Mean age (SD), year                            | 63.0(0.3) 52.4(0.4) 0.00 | 58.5(0.4) 57.8(0.4) 0.25 |
| Age group, year                                | 0.00             | 1.00             |
| <45                                            | 146(7.3) 553(30.3) 142(13.9) |
| 45–49                                          | 111(5.6) 191(10.5) 105(10.3) |
| 50–54                                          | 174(8.7) 202(11.1) 103(10.1) |
| 55–59                                          | 265(13.3) 243(13.3) 152(14.9) |
| 60–64                                          | 334(16.7) 229(12.6) 183(17.9) |
| 65–69                                          | 327(16.4) 178(9.8) 151(14.8) |
| 70–74                                          | 303(15.2) 114(6.3) 99(9.7) |
| 75–79                                          | 221(11.1) 66(3.6) 58(5.7) |
| 80–84                                          | 83(4.2) 37(2.0) 22(2.2) |
| 85+                                            | 31(1.6) 11(0.6) 7(0.7) |
| Women                                          | 1,488(74.6) 1,270(69.6) 0.00 | 702(68.7) 702(68.7) 1.00 |

**Comorbidity**

- Hypertension: 441(22.1) 194(10.6) 0.00 148(14.5) 167(16.3) 0.24
- Hyperlipidemia: 231(11.6) 92(5.0) 0.00 75(7.3) 69(6.8) 0.60
- Diabetes mellitus: 251(12.6) 198(10.9) 0.10 103(10.1) 144(14.1) 0.01
- COPD: 39(2.0) 78(4.3) 0.00 12(1.2) 64(6.3) 0.00

**Outcomes**

- CVD: 166(8.3) 139(7.6) 0.43 53(5.2) 105(10.3) 0.00
- IHD: 76(3.8) 44(2.4) 0.01 23(2.3) 34(3.3) 0.14
- MI: 3(0.15) 2(0.11)
- CHF: 17(0.9) 21(1.2) 0.35 5(0.5) 18(1.8) 0.01
- Stroke: 74(3.7) 34(1.9) 0.00 29(2.8) 27(2.6) 0.79
- Arteriosclerosis: 216(10.8) 234(12.8) 0.06 65(6.4) 203(19.9) 0.00

Numbers are frequencies (percentages) unless otherwise specified, CVD: cardiovascular disease, IHD: ischaemic heart disease, MI: myocardial infarction, CHF: congestive heart disease, COPD: chronic obstructive pulmonary disease

[https://doi.org/10.1371/journal.pone.0180376.t001](https://doi.org/10.1371/journal.pone.0180376.t001)
### Table 2. Risk of cardiovascular diseases in rheumatoid arthritis (RA) compared with osteoarthritis (OA).

| Cardiovascular disease | Unmatched dataset OR (95%CI) | Matched dataset OR (95%CI) |
|------------------------|------------------------------|-----------------------------|
|                        | Unadjusted                   | Adjusted                    | Unadjusted                   | Adjusted                    |
| RA vs. OA              | 0.91(0.72–1.15)              | 1.86(1.42–2.43)*            | 2.09(1.49–2.95)*            | 2.19(1.49–3.21)*            |
| Age, per 5 years       | 1.42(1.34–1.50)*             | 1.38(1.30–1.47)*            | 1.42(1.31–1.54)*            | /                            |
| Women                  | 0.90(0.69–1.16)              | 0.94(0.71–1.24)             | 0.70(0.50–0.98)             | /                            |
| Hypertension           | 4.64(3.63–5.93)*             | 2.72(2.07–3.57)*            | 3.79(2.68–5.38)*            | 1.98(1.07–3.65)*            |
| Hyperlipidemia         | 2.33(1.68–3.23)*             | 1.81(1.26–2.58)*            | 1.67(0.98–2.85)             | 1.66(0.64–4.32)             |
| Diabetes mellitus      | 2.74(2.07–3.63)*             | 1.51(1.11–2.04)*            | 2.34(1.57–3.49)*            | 1.57(0.76–3.25)             |
| COPD                   | 2.63(1.62–4.29)*             | 1.21(0.71–2.05)             | 3.43(1.93–6.11)*            | 1.94(0.63–6.01)             |
| Stroke                 |                              |                             |                              |                              |
| RA vs. OA              | 0.49(0.33–0.74)*             | 1.11(0.71–1.74)             | 0.93(0.55–1.58)             | 1.13(0.57–2.25)             |
| Age, per 5 years       | 1.58(1.43–1.74)*             | 1.47(1.32–1.64)*            | 1.54(1.35–1.76)*            | /                            |
| Women                  | 0.83(0.55–1.26)              | 0.78(0.50–1.21)             | 0.75(0.44–1.31)             | /                            |
| Hypertension           | 7.38(4.99–10.92)*            | 3.84(2.50–5.90)*            | 7.44(4.33–12.79)*           | 4.80(1.65–13.93)*           |
| Hyperlipidemia         | 2.72(1.67–4.45)*             | 1.84(1.08–3.12)*            | 1.93(0.86–4.34)             | 1.21(0.26–5.62)             |
| Diabetes mellitus      | 2.60(1.66–4.06)*             | 1.22(0.76–1.96)             | 2.51(1.35–4.67)*            | 1.33(0.41–4.25)             |
| COPD                   | 1.91(0.82–4.44)              | 0.83(0.34–2.04)             | 2.05(0.72–5.81)             | 0.38(0.07–1.93)             |
| Ischaemic heart disease|                              |                             |                              |                              |
| RA vs. OA              | 0.62(0.43–0.91)*             | 1.47(0.97–2.24)             | 1.49(0.87–2.56)             | 1.83(0.94–3.56)             |
| Age, per 5 years       | 1.66(1.51–1.82)*             | 1.59(1.43–1.76)*            | 1.74(1.51–2.01)*            | /                            |
| Women                  | 1.01(0.69–1.52)              | 1.08(0.70–1.67)             | 0.78(0.45–1.34)             | /                            |
| Hypertension           | 6.49(4.48–9.39)*             | 3.37(2.25–5.05)*            | 4.57(2.67–7.83)*            | 4.40(1.28–15.05)*           |
| Hyperlipidemia         | 1.83(1.08–3.10)*             | 1.24(0.70–2.18)             | 1.58(0.66–3.74)             | 0.62(0.11–3.64)             |
| Diabetes mellitus      | 2.61(1.71–3.99)*             | 1.30(0.83–2.05)             | 1.99(1.04–3.81)             | 1.09(0.35–3.32)*            |
| COPD                   | 2.35(1.12–4.94)*             | 0.98(0.44–2.17)             | 2.59(1.01–6.69)             | 1.38(0.28–6.87)             |
| Congestive heart disease|                              |                             |                              |                              |
| RA vs. OA              | 1.36(0.71–2.58)              | 2.09(1.03–4.22)*            | 3.65(1.35–9.86)*            | 6.95(1.50–32.21)*           |
| Age, per 5 years       | 1.36(1.18–1.57)*             | 1.27(1.08–1.49)*            | 1.29(1.07–1.57)*            | /                            |
| Women                  | 0.47(0.25–0.90)*             | 0.57(0.29–1.10)             | 0.41(0.18–0.94)             | /                            |
| Hypertension           | 4.62(2.43–8.78)*             | 3.59(1.77–7.29)*            | 5.18(2.26–11.84)*           | 13.69(1.13–166.48)*         |
| Hyperlipidemia         | 0.29(0.04–0.22)              | 0.22(0.03–1.64)             | Exactly the same            | (omitted)                    |
| Diabetes mellitus      | 2.72(1.31–5.64)*             | 1.57(0.73–3.36)             | 2.04(0.75–5.55)             | 1.27(0.18–9.18)             |
| COPD                   | 4.96(1.90–12.95)*            | 2.05(0.72–5.80)             | 4.00(1.16–13.77)*           | 3.95(0.19–82.30)            |
| Atherosclerosis        |                              |                             |                              |                              |
| RA vs. OA              | 1.21(1.00–1.48)              | 2.49(1.97–3.13)*            | 3.65(2.72–4.90)*            | 4.95(3.36–7.28)*            |
| Age, per 5 years       | 1.31(1.26–1.37)*             | 1.31(1.25–1.38)*            | 1.30(1.22–1.38)*            | /                            |
| Women                  | 0.92(0.74–1.14)              | 0.96(0.76–1.21)             | 0.92(0.70–1.21)             | /                            |
| Hypertension           | 3.88(3.14–4.81)*             | 2.47(1.94–3.15)*            | 3.34(2.49–4.46)*            | 1.83(0.98–3.42)             |
| Hyperlipidemia         | 3.75(2.89–4.88)*             | 3.51(2.63–4.69)*            | 3.55(2.43–5.17)*            | 5.62(2.23–14.4)*            |
| Diabetes mellitus      | 2.20(1.71–2.84)*             | 1.21(0.92–1.60)             | 1.73(1.22–2.44)*            | 0.91(0.43–1.92)             |
| COPD                   | 3.24(2.14–4.89)*             | 1.61(1.02–2.54)*            | 3.05(1.84–5.07)*            | 1.31(0.35–4.87)             |

CI: confidence interval, COPD: chronic obstructive pulmonary disease. The number of observations for multivariate conditional logistic regression analysis for cardiovascular disease, ischaemic heart disease, congestive heart disease, stroke and atherosclerosis was 292, 106, 46, 108 and 404 respectively. *p<0.05

https://doi.org/10.1371/journal.pone.0180376.t002
controversial.[21, 22] Therefore, the CVD risk in Chinese people with RA comparing with the general population might be higher than the estimate in our study.

This study has several limitations. Firstly, the participants in this study were all inpatients consecutively admitted to a medical centre. Therefore, selection bias may be introduced, for inpatients are generally more severe in disease status than outpatients or community patients, but this situation may be even between RA cases and OA controls. Secondly, some covariables or confounders of CVD were not included in the analysis for they were absence in the database such as obesity, smoking and anti-rheumatic drugs. There is evidence that obesity is more prevalent in patients with OA than in RA.[17, 21] Thus, the risk of CVD in RA compared with OA may be higher if obesity was controlled for. Furthermore, diabetes and COPD were adjusted in the analysis, which are positively associated with obesity and smoking, thus their effect on CVD may be indirectly and partially adjusted. Thirdly, detailed analysis on sub-category of CVDs such as myocardial infarction was not possible due to the small number of events. Finally, the natural of the cross-sectional study design prevented us to yield a causal-relationship between RA and CVD.

In conclusion, Chinese people with RA were approximated 2 times more likely to have CVD, IHD, CHF and atherosclerosis compared with people with OA. Further longitudinal study is needed to establish the risk of total and specific CVD in Chinese people with RA.

Supporting information
S1 Table. ICD-10 codes of outcomes and covariates.
(SDOCX)

S2 Table. Sensitivity analysis using unmatched dataset adjusted for covariables and interaction terms with rheumatoid arthritis (RA). RA: rheumatoid arthritis; OA: osteoarthritis, COPD: chronic obstructive pulmonary disease; & Diabetes mellitus or hyperglycemia; $ No significant interaction term was detected; "Bayesian information criterion in favor of the model; *p<0.05.
(DOCX)

S1 File. Strobe checklist.
(DOC)

Acknowledgments
We owe thanks to Ms Yan Xu from the Department of Medical Records and Statistics, Sichuan Provincial Hospital for her expert advice on the ICD-10 codes in this study.

Author Contributions
Conceptualization: KZ, WZ.
Data curation: FHX KZ.
Formal analysis: KZ.
Methodology: KZ WZ CFK.
Project administration: HYL.
Resources: HYL.
Software: FHX KZ.
Supervision: WZ.

Writing – original draft: KZ.

Writing – review & editing: KZ FXX HYL QZ LB MY CFK WZ.

References
1. NICE. Rheumatoid arthritis: The management of rheumatoid arthritis in adults (CG79). National Institute for Health and Clinical Excellence; 2015.
2. Avina-Zubia JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis and rheumatism. 2008; 59(12):1690–7. https://doi.org/10.1002/art.24092 PMID: 19035419.
3. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007; 46(2):350–7. https://doi.org/10.1093/rheumatol/kei253 PMID: 16908509.
4. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003; 30(6):1196–202. Epub 2003/06/05. PMID: 12784389.
5. Sihtonen S, Korpela M, Laippala P, Mustonen J, Pasterнак A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scandinavian journal of rheumatology. 2004; 33(4):221–7. https://doi.org/10.1080/03009740410005845 PMID: 15370716.
6. Zeng XF, Zhu SL, Tan AC, Xie XP. Disease Burden and Quality of Life of Rheumatoid Arthritis in China: A Systematic Review. Chinese Journal of Evidence-based Medicine. 2013;(03):300–7 (In Chinese).
7. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Annals of the rheumatic diseases. 2011; 70(1):8–14. https://doi.org/10.1136/ard.2010.142133 PMID: 21109513.
8. NICE. NICE guideline: Osteoarthritis: care and management. National Institute for Health and Care Excellence; 2014.
9. Nielen MM, van Sijl AM, Peters MJ, Verheij RA, Schellevis FG, Nurmohamed MT. Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary care. BMC Musculoskeletal Disorder. 2012; 13:150. https://doi.org/10.1186/1471-2474-13-150 PMID: 22906083.
10. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the rheumatic diseases. 2010; 69(2):325–31. https://doi.org/10.1136/ard.2009.113696 PMID: 19773290.
11. Quan H, Sundaranarajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care. 2005; 43(11):1130–9. PMID: 16224307.
12. Li C, Wang X, Tang Y, An Y, Zhou Y, Guo S, et al. A multicenter study of coronary artery disease and its risk factors in rheumatoid arthritis in China Journal of Peking University (Health Sciences). 2012;(02):176–81 (In Chinese).
13. Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007–2008 China National Diabetes and Metabolic Disorders Study. European heart journal. 2012; 33(2):213–20. https://doi.org/10.1093/eurheartj/ehr205 PMID: 21719451.
14. Irisarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999; 340 (23):1773–80. https://doi.org/10.1056/NEJM199906103402301 PMID: 10362820.
15. Ungprasert P, Srivai N, Cheungpasitporn W, Davis JM Li. Risk of incident chronic obstructive pulmonary disease in patients with rheumatoid arthritis: A systematic review and meta-analysis. Joint, bone, spine: revue du rhumatisme. 2016; 83(3):290–9. https://doi.org/10.1016/j.jbspin.2015.05.016 PMID: 26709254.
16. Raftery AE. Bayesian model selection in social research. In Vol. 25 of Sociological Methodolog. P. V. Marsden ed. Oxford: Blackwell; 1995.
17. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Annals of the rheumatic diseases. 2009; 68(9):1395–400. Epub 2008/08/14. https://doi.org/10.1136/ard.2008.094151 PMID: 18697775.
18. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Wallius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISK (AMORIS) Study. Annals of the rheumatic diseases. 2010; 69(11):1996–2001. https://doi.org/10.1136/ard.2009.126128 PMID: 20551156.

19. Chung WS, Lin CL, Peng CL, Chen YF, Lu CC, Sung FC, et al. Rheumatoid arthritis and risk of acute myocardial infarction—a nationwide retrospective cohort study. International journal of cardiology. 2013; 168(5):4750–4. https://doi.org/10.1016/j.ijcard.2013.07.233 PMID: 23938220.

20. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015; 11(7):390–400. https://doi.org/10.1038/nrrheum.2015.40 PMID: 25825281

21. Rahman MM, Kopec JA, Anis AH, Cibere J, Goldsmith CH. Risk of cardiovascular disease in patients with osteoarthritis: a prospective longitudinal study. Arthritis Care Res (Hoboken). 2013; 65(12):1951–8. https://doi.org/10.1002/acr.22092 PMID: 23925995.

22. Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. European journal of preventive cardiology. 2016; 23(9):938–46. Epub 2015/10/16. https://doi.org/10.1177/2047487315610663 PMID: 26464295.